We have developed a dual-antigen COVID-19 vaccine incorporating genes for a modified SARS-CoV-2 spike protein (S-Fusion) and the viral nucleocapsid (N) protein with an Enhanced T-cell Stimulation Domain (N-ETSD) to increase the potential for MHC class II responses. The vaccine antigens are delivered by a human adenovirus serotype 5 platform, hAd5 [E1-, E2b-, E3-], previously demonstrated to be effective in the presence of Ad immunity. Vaccination of rhesus macaques with the hAd5 S-Fusion + N-ETSD vaccine by subcutaneous prime injection followed by two oral boosts elicited neutralizing anti-S IgG and T helper cell 1-biased T-cell responses to both S and N that protected the upper and lower respiratory tracts from high titer (1 x 10 6 TCID 50 ) SARS-CoV-2 challenge. Notably, viral replication was inhibited within 24 hours of challenge in both lung and nasal passages, becoming undetectable within 7 days post-challenge.
【저자키워드】 COVID-19, Vaccine, protection, lung, non-human primate (NHP), dual antigen, SARS-CoV-2 challenge, nasal passages, 【초록키워드】 SARS-CoV-2, COVID-19 vaccine, Immunity, T-cell Response, Spike protein, Adenovirus, Protein, Viral, viral replication, SARS-CoV-2 spike protein, MHC class II, Neutralizing, T-cell, respiratory, fusion, platform, T-cell responses, boost, anti-S IgG, Stimulation, rhesus macaques, rhesus macaque, Lower respiratory tract, followed by, 24 hours, T helper cell, helper cell, serotype, injection, upper and lower respiratory tracts, vaccine antigen, TCID, MHC class, enhanced, responses, effective, inhibited, demonstrated, elicited, the viral nucleocapsid, 24 hour, undetectable, 【제목키워드】 SARS-CoV-2, delivery, challenge, oral, Subcutaneous, NHP, Against,